---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-25-000028"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:14:55.217383+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M

## Summary
- Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.
- FY 2024 net loss $232.6M ($3.58 diluted EPS) vs $133.1M ($2.20); R&D spend dropped to $227.7M.
- Cash $706.7M at Dec 31; 2025 guidance $535-585M, runway into 2028.
- Pipeline: XmAb942 healthy-volunteer data 1H 2025; XmAb819 ccRCC data 2H 2025; plamotamab RA Ph1b/2a start 1H 2025.
- Vudalimab development paused; milestone revenue of $30M (Amgen) and $4M (Novartis) received in 2025.

## SEC filing metadata
- accession: 0001326732-25-000028
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000028/0001326732-25-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673225000028/xncr-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-25-000028
- JSON: https://secwatch.observer/filing/0001326732-25-000028.json
- Plain text: https://secwatch.observer/filing/0001326732-25-000028.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.